Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. (2016)

Peer-Reviewed Study · Taneja SS, Bennett J, Coleman J, Grubb R, Andriole G, Reiter RE, Marks L, Azzouzi AR, Emberton M · June 9, 2016

Taneja SS et al., 2016-06-09: US multicentre phase I/II dose-escalation trial of WST11 (padeliporfin) vascular-targeted photodynamic therapy hemi-ablation in 30 men with unilateral low-risk prostate cancer. No methylene blue involved.

A total of 30 men with unilateral, low volume, Gleason 3 + 3 prostate cancer were enrolled at 5 centers after local institutional review board approval.

Taneja SS et al., 2016-06-09: US multicentre phase I/II dose-escalation trial of WST11 (padeliporfin) vascular-targeted photodynamic therapy hemi-ablation in 30 men with unilateral low-risk prostate cancer. No methylene blue involved. C3. Study type: phase I/II multicentre trial. N: 30 men, 5 US centres. Drug: WST11/TOOKAD Soluble (padeliporfin), dose and light energy escalated. Route: intravenous drug plus interstitial fibres. Funder: Medical Research Council (UK) MR/M009092/1 and NCI P30 CA008748 per GrantList. Conflicts: not captured. Comparator: within-trial dose escalation, no untreated arm. The sensitiser is not methylene blue. Study type: uncontrolled series.